

SHEET 1 OF 3

FORM PTO/A-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 2848-28-PUS-1-1	SERIAL NO. 10/655,889
	APPLICANT SCHMIDT	
	FILING DATE September 4, 2003	GROUP ART 1651

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
VA	1	6,365,164	4-2-2002	Schmidt	424	239.1	
VA	2	5,837,265	11-17-1998	Montal et al.	424	239.1	
VA	3	5,437,291	8/1/95	Pasricha et al.	128	898	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
VA	4	WO 99/03483	1/1999	PCT				


OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

VA	5	* "AFUD Prostate Cancer Treatment: Treatment"; <i>American Foundation for Urologic Disease</i> ; (at least as early as August 5, 2003)
↑	6	* Bardsley; "The Neurogenic Bladder"; <i>Art & Science Continece</i> ; (January 7, 2000); pp. 39-41
	7	* Burnstein et al.; "Prostatitis: A Difficult Diagnosis"; <i>DeKalb Clinic Urology</i> ; (at least as early as August 20, 2003); 3 pp.
	8	Bruschini et al., "Neurologic Control of Prostatic Secretion in the Dog"; <i>Invest. Urol.</i> , 15(4):288-290 (January 1978)
	9	* "Continence Management"; <i>The Prostate Cancer Charity</i> ; (at least as early as August 8, 2003); 6 pp.
	10	* Crawford; "Prostate Cancer"; <i>Best Doctors</i> ; (June 7, 2000); 6 pp.
	11	Downie et al., "Evidence for a Spinal Site of Action of Clonidine on Somatic and Viscerosomatic Reflex Activity Evoked on the Pudendal Nerve in Cats"; <i>J. Pharmacol. Exp. Ther.</i> , 246(1):352-358 (May 1988)
VA	12	Dykstra et al., "Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study"; <i>Arch. Phys. Med. Rehabil.</i> , 71:24-26 (January 1990)

EXAMINER V. Freeman	DATE CONSIDERED 3-02-06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2848-28-PUS-1-1	SERIAL NO. 10/655,889
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT SCHMIDT	
	FILING DATE September 4, 2003	GROUP ART 1651

✓A	13	* Epstein; "Gleason Score 2 - 4 Adenocarcinoma of the Prostate on Needle Biopsy"; <i>American Journal of Surgical Pathology</i> , (2000) Vol. 24(4); pp. 477-78
↑	14	Håkanson et al., "Multiple Tachykinin Pools in Sensory Nerve Fibres in the Rabbit Iris"; <i>Neuroscience</i> , 21(3):943-950 (1987)
	15	Higgins et al., "Studies on the Structure and Intrinsic Innervation of the Normal Human Prostate"; <i>Prostate Suppl.</i> , 2:5-16 (1989)
	16	* "Inconsistence and the Prostate"; <i>Phoenix5</i> ; (at least as early as August 5, 2003); 11 pp.
	17	Ishizuka et al., "Urodynamic Effects of Intravesical Resiniferatoxin and Capsaicin in Conscious Rats With and Without Outflow Obstruction"; <i>J. Urology</i> , 154:611-616 (August 1995)
	18	Joo et al., "Initial North American Experience with Botulinum Toxin Type A for Treatmetn of Anismus"; <i>Dis. Colon. Rectum</i> , 39(10):1107-1111 (October 1996)
	19	Lapor "Role of Long-Acting Selective Alpha-1 Blockers in the Treatment of Benign Prostatic Hyperplasia"; <i>Urol. Clin. North Am.</i> , 17(3):651-658 (August 1990)
	20	Maggi et al., "Cystometric Evidence That Capsaicin-Sensitive Nerves Modulate the Afferent Branch of Micturition Reflex in Humans"; <i>J. Urol.</i> , 142:150-154 (July 1989)
	21	* Marieb; "Chapter 13: Peripheral Nervous System and Reflex Activity"; <i>Human Anatomy and Physiology</i> , 5 th Ed.; (at least as early as August 8, 2003) 5 pp.
	22	Mocchetti, "Pharmacology of Neuronal Gene Expression"; <i>Pharmacol. Res.</i> , 21(Suppl. 2):85-95 (1989)
	23	* Peak; "Understanding Continence"; <i>The Interdisciplinary Journal of Rehabilitation</i> ; (March 2002); 9 pp.
	24	* "Prostate Cancer: Prostate Cancer Transrectal Biopsies"; (at least as early as August 20, 2003); 9 pp.
	25	* "Prostate Cancer: Tumor Grading"; <i>UPMC Cancer Centers</i> ; (2003); 2 pp.
	26	* "Prostate Cancer: What are the Treatment Options?"; <i>NSW Health</i> ; (January 4, 2002); 2 pp.
	27	* "Prostate Cancer (PDQ®): Treatment"; <i>National Cancer Institute</i> ; (July 17, 2003); 11 pp.
	28	* "Prostate Gland and Urinary Problems"; <i>Better Health Channel</i> ; (October 10, 2001); 10 pp.
	29	Schurch et al., <i>J. Urol.</i> , 155:1023-1029 (1996)
	30	* Strum; "Is There a Correct Way to Treat Prostate Cancer"; <i>Prostate Cancer Research Institute</i> ; 28 pp. (at least as early as 9/12/2000)
	31	* Strum; "Predictive and Prognostic Information in the Counseling of Patients Recently Diagnosed with Prostate Cancer"; <i>The Prostate Cancer Research Institute</i> ; (at least as early as September 12, 2000); 21 pp.
	32	* "The Side Effects of Treatment"; <i>Varian Medical System</i> ; (1999-2003); 2 pp.
✓A	33	Tim et al., <i>Botulinum Toxin Therapy</i> , 9(6):327-332 (1992)
	34	* "Treating Prostate Disease"; <i>The Cleveland Clinic</i> ; (January 28, 1999); 3 pp.

EXAMINER 	DATE CONSIDERED 3-02-06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2848-28-PUS-1-1	SERIAL NO. 10/655,889
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT SCHMIDT	
	FILING DATE September 4, 2003	GROUP ART 1651

✓A	35	• "Treatment for Localized Disease: Observation and Monitoring of PSA"; <i>Prostate Cancer Research Institute</i> ; (at least as early as August 11, 2003); 1 p.
✓B	36	• "Questions and Answers About the Prostate-Specific Antigen (PSA) Test"; <i>National Cancer Institute</i> ; (January 11, 2001); 5 pp.
✓B	37	• "Understanding Gleason Grading"; <i>Phoenix5</i> ; (May 14, 1997); 8 pp.

EXAMINER <i>V. A. Remora</i>	DATE CONSIDERED <i>3-02-06</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/655,889	
			Filing Date	September 4, 2003	
			First Named Inventor	SCHMIDT	
			Art Unit	1651	
			Examiner Name	Afremova, V.	
Sheet	1	of	1	Attorney Docket Number	2848-28-PUS-1-1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² : Number ² : Kind Code ² (if known)						
		PCT	-					
			-					

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
VA		Beleggia et al., Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract)
		Chancellor et al., J Urol 2003 Apr;169 (Supp 4):351
		DasGupta et al., Urogynaecology 2003, 13:293-299
		Fowler et al., British J of Urol., Oct. 22, 1991, 387-389
		Kuo, Hann-Chorng, J Urol 2003 Nov, 170:1908-1912
		Leippold et al., Eur Urol 44 (2003) 165-174
		Nanninga, John B., Oxins (1993) p 589-590
VA		Smith et al., Int Urogynecol J (2002) 13:55-56

Examiner Signature	V. Afremova	Date Considered	3-02-2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.